U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07143097) titled 'Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer' on Aug. 09.
Brief Summary: Eligible patients was assigned in a 1:1 ratio to receive either low-dose capecitabine maintenance (intervention group) which is newly diagnostic to be planned to receive capecitabine after finishing the standard adjuvant treatment or observation (control group) within 4 weeks after completion of standard adjuvant chemotherapy.
Study Start Date: Nov. 01, 2021
Study Type: INTERVENTIONAL
Condition:
Triple -Negative Breast Cancer
Intervention:
DRUG: capecitabine
capecitabine 650 mg / m2 twice per day for one...